|
Other anticoagulants
Citations 1-10 of 93 total displayed.
|
Most recent content
(17 Nov 2009):
|
- Correspondence
Response to Letter Regarding Article, "Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial"
- Barry M. Massie, Susan E. Ammon, Joseph F. Collins, William F. Krol, Paul W. Armstrong, John G.F. Cleland, Michael Ezekowitz, Syed M. Jafri, Christopher M. O'Connor, Kevin A. Schulman, Koon Teo, and Stuart Warren
Circulation 2009;120:e165, doi:10.1161/CIRCULATIONAHA.109.884650
[Full text]
- Vascular Medicine
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
- John W. Eikelboom, Daniel J. Quinlan, and Martin O'Donnell
Circulation 2009;120:2006-2011; published online before print as doi:10.1161/CIRCULATIONAHA.109.872630
[Abstract]
[Full text]
|
Past content
(since Jan 2001):
|
- Articles
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
- John W. Eikelboom, Daniel J. Quinlan, and Martin O'Donnell
Circulation published November 2, 2009, doi:10.1161/CIRCULATIONAHA.109.872630
[Abstract]
- Editorials
New Therapies for Stroke Prevention in Atrial Fibrillation: The Long Road to Enhanced Efficacy
- Jane E. Freedman and Bernard J. Gersh
Circulation 2009;120:1024-1026; published online before print as doi:10.1161/CIRCULATIONAHA.109.893362
[Full text]
- Arrhythmia/Electrophysiology
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation
- David J. Ellis, Mohammed Haris Usman, Peter G. Milner, Daniel M. Canafax, and Michael D. Ezekowitz
Circulation 2009;120:1029-1035; published online before print as doi:10.1161/CIRCULATIONAHA.109.856120
[Abstract]
[Full text]
- Articles
New Therapies for Stroke Prevention in Atrial Fibrillation. The Long Road to Enhanced Efficacy
- Jane E. Freedman and Bernard J. Gersh
Circulation published September 9, 2009, doi:10.1161/CIRCULATIONAHA.109.893362
[Abstract]
- Articles
New Therapies for Stoke Prevention in Atrial Fibrillation. The Long Road to Enhanced Efficacy
- Jane E. Freedman and Bernard J. Gersh
Circulation published September 8, 2009, doi:10.1161/CIRCULATIONAHA.109.893362
[Abstract]
- Articles
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation
- David J. Ellis, Mohammed Haris Usman, Peter G. Milner, Daniel M. Canafax, and Michael D. Ezekowitz
Circulation published September 8, 2009, doi:10.1161/CIRCULATIONAHA.109.856120
[Abstract]
- Coronary Heart Disease
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
- APPRAISE Steering Committee and Investigators
Circulation 2009;119:2877-2885; published online before print as doi:10.1161/CIRCULATIONAHA.108.832139
[Abstract]
[Full text]
- Articles
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
- APPRAISE Steering Committee and Investigators
Circulation published May 26, 2009, doi:10.1161/CIRCULATIONAHA.108.832139
[Abstract]
|
|
